Injective Labs and 21Shares have launched the first INJ-linked ETP on Euronext Amsterdam and Paris. This fund allows users to gain exposure to INJ tokens via major traditional financial exchanges and brokerages while capturing staking rewards.
The ETP, supported by 25 banks and brokerages, is a significant milestone for Injective, marking its integration with traditional financial markets. This product bridges the gap between traditional finance and decentralized markets, paving the way for broader institutional participation in $INJ.
AINJ is one of the few crypto tokens with an associated ETP, underscoring its importance and innovation. With $128.6 million in assets under management and a 2.5% fee, it tracks Injective’s performance and captures staking yield for reinvestment, offering an estimated 19.38% staking reward.
The ETP is physically backed by INJ in cold storage and regulated under the Euronext Rule Book. With a market cap of $2.4 billion, Injective stands to benefit from increased institutional and retail participation, especially as interest in digital asset ETPs grows.
This launch is a strategic advancement for broader adoption and integration of digital assets in traditional finance.
